<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">zabmedvestnik</journal-id><journal-title-group><journal-title xml:lang="ru">Забайкальский медицинский вестник</journal-title><trans-title-group xml:lang="en"><trans-title>Transbaikalian Medical Bulletin</trans-title></trans-title-group></journal-title-group><issn pub-type="epub">1998-6173</issn><publisher><publisher-name>Читинская государственная медицинская академия</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.52485/19986173_2022_3_18</article-id><article-id custom-type="elpub" pub-id-type="custom">zabmedvestnik-185</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL RESEARCH</subject></subj-group></article-categories><title-group><article-title>УРОВЕНЬ АУТОАНТИТЕЛ К ДОФАМИНОВЫМ И NMDA РЕЦЕПТОРАМ У ДЕТЕЙ В ЗАВИСИМОСТИ ОТ СТЕПЕНИ ТЯЖЕСТИ ДИАБЕТИЧЕСКОГО КЕТОАЦИДОЗА</article-title><trans-title-group xml:lang="en"><trans-title>LEVELS OF AUTOANTIBODIES AGAINST DOPAMINE AND NMDA RECEPTORS IN CHILDREN DEPENDING ON THE SEVERITY OF DIABETIC KETOACIDOSIS</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Быков</surname><given-names>Ю. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Bykov</surname><given-names>Yu. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>355017, Ставрополь, ул. Мира, 310</p></bio><bio xml:lang="en"><p>355017, Stavropol, Mira str., 310</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Батурин</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Baturin</surname><given-names>V. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>355017, Ставрополь, ул. Мира, 310</p></bio><bio xml:lang="en"><p>355017, Stavropol, Mira str., 310</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Волков</surname><given-names>Е. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Volkov</surname><given-names>E. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>355017, Ставрополь, ул. Мира, 310</p></bio><bio xml:lang="en"><p>355017, Stavropol, Mira str., 310</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное образовательное учреждение высшего образования «Ставропольский государственный медицинский университет» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Stavropol State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>05</day><month>08</month><year>2024</year></pub-date><volume>0</volume><issue>3</issue><fpage>18</fpage><lpage>26</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Быков Ю.В., Батурин В.А., Волков Е.Е., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Быков Ю.В., Батурин В.А., Волков Е.Е.</copyright-holder><copyright-holder xml:lang="en">Bykov Y.V., Baturin V.A., Volkov E.E.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.zabmedvestnik.ru/jour/article/view/185">https://www.zabmedvestnik.ru/jour/article/view/185</self-uri><abstract><sec><title>Цель исследования</title><p>Цель исследования. Оценить и проанализировать уровень аутоантител (ААТ) к дофаминовым и NMDA рецепторам у детей в зависимости от степени тяжести диабетического кетоацидоза (ДКА).</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. В исследование включено 76 детей, из них 38 детей (группа исследования) составили пациенты с сахарным диабетом (СД) 1-го типа на фоне диабетического кетоацидоза (ДКА) и 38 условно здоровых детей (группа контроля). Дети из группы исследования, были разделены на три подгруппы: ДКА 1 степени (n=22); ДКА 2 степени (n=12); ДКА 3 степени (n=4). Выполнено определение ААТ в сыворотке крови к дофаминовым рецепторам второго типа (DAR2) и к глутаматергическим рецепторам первого типа (NMDAR1). При обработке статистических данных использовался критерий Манна-Уитни, Краскела-Уоллиса, коэффициент ранговой корреляции Спирмена. Уровень статистической значимости был принят за p&lt;0,05.</p></sec><sec><title>Результаты</title><p>Результаты. Максимальные клинические нарушения уровня сознания и биохимических показателей, выявлены у детей с ДКА 3 степени. У всех пациентов с ДКА диагностировано повышение средних значений ААТ как к NMDAR1 - 3,82 [3,0-5,59] ЕД/мл, по равнению с условно здоровыми детьми - 1,12 [0,65-1,64] ЕД/мл (р=0,000) и ААТ к DAR2 - 7,24 [3,84-12,19] ЕД/мл, по сравнению с пациентами из группы контроля - 2,13 [1,45-3,15] ЕД/мл (р=0,000). Обнаружено, что степень повышения ААТ к NMDAR1 и DAR2 зависела от клинической тяжести ДКА (максимальные концентрации выявлены при ДКА 3 степени). Показана корреляционная связь между высокими значениями ААТ и нарушениями уровня сознания.</p></sec><sec><title>Заключение</title><p>Заключение. Полученные результаты свидетельствуют о нарушении глутаматергической и дофаминергической систем при ДКА у детей с СД 1-го типа, что указывает на наличие мозговой дисфункции.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>The aim of the research</title><p>The aim of the research. To measure and analyze the levels of autoantibodies (AAB) against dopamine and NMDA receptors in children in relation to the severity of diabetic ketoacidosis (DKA).</p></sec><sec><title>Materials and methods</title><p>Materials and methods. The study included 76 children, of which 38 children (study group) had type 1 diabetes mellitus (DM) and diabetic ketoacidosis (DKA) and 38 were apparently healthy children (control group). The study group children were divided into three subgroups: grade 1 DKA (n=22); grade 2 DKA (n=12); and grade 3 DKA (n=4). Blood serum samples were analyzed to measure the levels of AAB to type 2 dopamine receptors (DAR2) and type 1 glutamatergic receptors (NMDAR1). Statistical data were processed using the Mann-Whitney test, Kruskel-Wallis test, and Spearman's rank correlation coefficient. The statistical significance level was specified as p&lt;0.05.</p></sec><sec><title>Results</title><p>Results. The largest clinical impairments in the level of consciousness and biochemical parameters were discovered in children with grade 3 DKA. All patients with DKA had elevated mean levels of AAB against both NMDAR1, amounting to 3.82 [3.0-5.59] U/mL compared with 1.12 [0.65-1.64] U/mL (p=0.000) in apparently healthy children, and DAR2, amounting to 7.24 [3.84-12.19] U/mL compared with 2.13 [1.45-3.15] U/mL (p=0.000) in the control group patients. The elevation of the levels of AAB against NMDAR1 and DAR2 was discovered to depend on the clinical severity of DKA (with the maximal concentrations found in grade 3 DKA). A correlation was shown to exist between elevated levels of AAB and consciousness impairments.</p></sec><sec><title>Conclusion</title><p>Conclusion. The obtained results indicate the impairment of the glutamatergic and dopaminergic systems in DKA in children with type 1 DM, which points at the presence of brain dysfunction.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>сахарный диабет</kwd><kwd>диабетический кетоацидоз</kwd><kwd>аутоантитела</kwd><kwd>дофаминовые рецепторы</kwd><kwd>NMDA рецепторы</kwd><kwd>дети</kwd></kwd-group><kwd-group xml:lang="en"><kwd>diabetes mellitus</kwd><kwd>diabetic ketoacidosis</kwd><kwd>autoantibodies</kwd><kwd>dopamine receptors</kwd><kwd>NMDA receptors</kwd><kwd>children</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">исследование не имело спонсорской поддержки</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Chiarelli F., Rewers M., Phillip M. Screening of Islet Autoantibodies for Children in the General Population: a Position Statement endorsed by the European Society for Pediatric Endocrinology. Horm Res Paediatr. 2022. DOI: 10.1159/000525824. Online ahead of print.</mixed-citation><mixed-citation xml:lang="en">Chiarelli F., Rewers M., Phillip M. Screening of Islet Autoantibodies for Children in the General Population: a Position Statement endorsed by the European Society for Pediatric Endocrinology. Horm Res Paediatr. 2022. DOI: 10.1159/000525824. Online ahead of print.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Pasi R., Ravi K.S. Type 1 diabetes mellitus in pediatric age group: A rising endemic. J Family Med Prim Care. 2022. 11(1). 27-31. DOI: 10.4103/jfmpc.jfmpc_975_21</mixed-citation><mixed-citation xml:lang="en">Pasi R., Ravi K.S. Type 1 diabetes mellitus in pediatric age group: A rising endemic. J Family Med Prim Care. 2022. 11(1). 27-31. DOI: 10.4103/jfmpc.jfmpc_975_21</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Raghunathan V., Jevalikar G., Dhaliwal M., Singh D., Sethi S.K., Kaur P., Singhi S.C. Risk Factors for Cerebral Edema and Acute Kidney Injury in Children with Diabetic Ketoacidosis. Indian J Crit Care Med. 2021. 25(12). 1446-1451. DOI: 10.5005/jp-journals-10071-24038</mixed-citation><mixed-citation xml:lang="en">Raghunathan V., Jevalikar G., Dhaliwal M., Singh D., Sethi S.K., Kaur P., Singhi S.C. Risk Factors for Cerebral Edema and Acute Kidney Injury in Children with Diabetic Ketoacidosis. Indian J Crit Care Med. 2021. 25(12). 1446-1451. DOI: 10.5005/jp-journals-10071-24038</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Baszyńska-Wilk M., Wysocka-Mincewicz M., Wajda-Cuszlag M., Świercz A., Szalecki M. Letter to the Editor: Central Nervous System Complications in Diabetic Ketoacidosis. Pediatr Endocrinol Rev. 2019. 17(1):47-49. DOI: 10.17458/per.vol17.2019.le.bwwmwc.nervouscomplicationsdiabetic</mixed-citation><mixed-citation xml:lang="en">Baszyńska-Wilk M., Wysocka-Mincewicz M., Wajda-Cuszlag M., Świercz A., Szalecki M. Letter to the Editor: Central Nervous System Complications in Diabetic Ketoacidosis. Pediatr Endocrinol Rev. 2019. 17(1):47-49. DOI: 10.17458/per.vol17.2019.le.bwwmwc. nervouscomplicationsdiabetic.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Gardoni F., Stanic J., Scheggia D., Benussi A., Borroni B., Di Luca M. NMDA and AMPA Receptor Autoantibodies in Brain Disorders: From Molecular Mechanisms to Clinical Features. Cells. 2021. 10(1). 77. DOI: 10.3390/cells10010077</mixed-citation><mixed-citation xml:lang="en">Gardoni F., Stanic J., Scheggia D., Benussi A., Borroni B., Di Luca M. NMDA and AMPA Receptor Autoantibodies in Brain Disorders: From Molecular Mechanisms to Clinical Features. Cells. 2021. 10(1). 77. DOI: 10.3390/cells10010077</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Arinuma Y. Antibodies and the brain: anti-N-methyl-D-aspartate receptor antibody and the clinical effects in patients with systemic lupus erythematosus. Curr Opin Neurol. 2018. 31(3). 294-299. DOI: 10.1097/WCO.0000000000000554</mixed-citation><mixed-citation xml:lang="en">Arinuma Y. Antibodies and the brain: anti-N-methyl-D-aspartate receptor antibody and the clinical effects in patients with systemic lupus erythematosus. Curr Opin Neurol. 2018. 31(3). 294-299. DOI: 10.1097/WCO.0000000000000554</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Klein M.O., Battagello D.S., Cardoso A.R., Hauser D.N., Bittencourt J.C., Correa R.G. Dopamine: Functions, Signaling, and Association with Neurological Diseases. Cell Mol Neurobiol. 2019. 39(1). 31-59. DOI: 10.1007/s10571-018-0632-3</mixed-citation><mixed-citation xml:lang="en">Klein M.O., Battagello D.S., Cardoso A.R., Hauser D.N., Bittencourt J.C., Correa R.G. Dopamine: Functions, Signaling, and Association with Neurological Diseases. Cell Mol Neurobiol. 2019. 39(1). 31-59. DOI: 10.1007/s10571-018-0632-3</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Dale R.C., Merheb V., Pillai S., Wang D., Cantrill L., Murphy T.K., Ben-Pazi H., Varadkar S., Aumann T.D., Horne M.K., Church A.J., Fath T., Brilot F. Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders. Brain. 2012. 135(11). 3453-68. DOI: 10.1093/brain/aws256</mixed-citation><mixed-citation xml:lang="en">Dale R.C., Merheb V., Pillai S., Wang D., Cantrill L., Murphy T.K., Ben-Pazi H., Varadkar S., Aumann T.D., Horne M.K., Church A.J., Fath T., Brilot F. Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders. Brain. 2012. 135(11). 3453-68. DOI: 10.1093/brain/aws256</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Быков Ю.В., Батурин В.А., Углова Т.А. Оценка уровней аутоантител к NMDA и дофаминовым рецепторам у детей больных сахарным диабетом I типа в зависимости от тяжести течения заболевания. Медицина. 2020. 8(2). 73-80. DOI: 10.29234/2308-9113-2020-8-2-73-80</mixed-citation><mixed-citation xml:lang="en">Bykov Yu.V., Baturin V.A., Uglova T.A. Estimating the levels of autoantibodies to NMDA and dopamine receptors in children with diabetes mellitus type I, subject to the condition severity. Medicine. 2020. 8(2). 73-80. in Russian. DOI: 10.29234/2308-9113-2020-8-2-73-80</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Федеральные клинические рекомендации (протоколы) по ведению детей с эндокринными заболеваниями. Под ред. И.И. Дедова и В.А. Петерковой. М. Практика. 2014. 442.</mixed-citation><mixed-citation xml:lang="en">Federal clinical guidelines (protocols) for the management of children with endocrine diseases. Edited by I.I. Dedov and V.A. Peterkova. M. Praktika. 2014. 442. in Russian.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Hanas R., Donaghue K.C., Klingensmith G., Swift P.G. ISPAD clinical practice consensus guidelines 2009 compendium. Introduction. Pediatr Diabetes. 2009. 10(12). 1-2. DOI: 10.1111/j.1399-5448.2009.00577.x</mixed-citation><mixed-citation xml:lang="en">Hanas R., Donaghue K.C., Klingensmith G., Swift P.G. ISPAD clinical practice consensus guidelines 2009 compendium. Introduction. Pediatr Diabetes. 2009. 10(12). 1-2. DOI: 10.1111/j.1399-5448.2009.00577.x</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Braine M.E., Cook N. The Glasgow Coma Scale and evidence-informed practice: a critical review of where we are and where we need to be. J Clin Nurs. 2017. 26(1-2). 280-293. DOI: 10.1111/jocn.13390</mixed-citation><mixed-citation xml:lang="en">Braine M.E., Cook N. The Glasgow Coma Scale and evidence-informed practice: a critical review of where we are and where we need to be. J Clin Nurs. 2017. 26(1-2). 280-293. DOI: 10.1111/jocn.13390</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 10-й выпуск (дополненный). М. 2021. DOI: 10.14341/DM12802</mixed-citation><mixed-citation xml:lang="en">Algorithms of specialized medical care for patients with diabetes mellitus. Edited by I.I. Dedov, M.V. Shestakova, A.Yu. Mayorov. 10th issue (expanded). M. 2021. in Russian. DOI: 10.14341/DM12802</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Burcul I., Arambasic N., Polic B., Kovacevic T., Bartulovic I., Catipovic Ardalic T., Markic J. Medicina (Kaunas). Characteristics of Children with Diabetic Ketoacidosis Treated in Pediatric Intensive Care Unit: Two-Center Cross-Sectional Study in Croatia. 2019. 55(7). 362. DOI: 10.3390/medicina55070362</mixed-citation><mixed-citation xml:lang="en">Burcul I., Arambasic N., Polic B., Kovacevic T., Bartulovic I., Catipovic Ardalic T., Markic J. Medicina (Kaunas). Characteristics of Children with Diabetic Ketoacidosis Treated in Pediatric Intensive Care Unit: Two-Center Cross-Sectional Study in Croatia. 2019. 55(7). 362. DOI: 10.3390/medicina55070362</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
